Fresenius Medical Care (NYSE:FMS) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Fresenius Medical Care (NYSE:FMS) in a research report issued on Monday. The firm set a “strong-buy” rating on the stock.

Separately, Truist Financial decreased their price objective on Fresenius Medical Care from $24.00 to $22.00 and set a “hold” rating on the stock in a report on Wednesday, July 31st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Fresenius Medical Care currently has an average rating of “Hold” and an average target price of $22.00.

Fresenius Medical Care Price Performance

Shares of NYSE:FMS opened at $21.31 on Monday. The firm has a market capitalization of $12.51 billion, a price-to-earnings ratio of 23.94, a PEG ratio of 1.08 and a beta of 0.90. The stock’s 50 day moving average is $19.67 and its 200-day moving average is $19.95. Fresenius Medical Care has a twelve month low of $16.37 and a twelve month high of $22.76. The company has a quick ratio of 1.09, a current ratio of 1.46 and a debt-to-equity ratio of 0.45.

Fresenius Medical Care (NYSE:FMS) last posted its quarterly earnings results on Tuesday, July 30th. The company reported $0.38 earnings per share for the quarter, hitting the consensus estimate of $0.38. Fresenius Medical Care had a return on equity of 5.48% and a net margin of 2.72%. The company had revenue of $5.13 billion during the quarter, compared to the consensus estimate of $5.28 billion. Sell-side analysts forecast that Fresenius Medical Care will post 1.51 EPS for the current fiscal year.

Hedge Funds Weigh In On Fresenius Medical Care

Several institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its position in Fresenius Medical Care by 21.8% in the 1st quarter. GAMMA Investing LLC now owns 4,230 shares of the company’s stock worth $82,000 after purchasing an additional 758 shares during the period. ORG Partners LLC purchased a new stake in Fresenius Medical Care in the 1st quarter worth about $110,000. SageView Advisory Group LLC purchased a new stake in Fresenius Medical Care in the 1st quarter worth about $127,000. Signaturefd LLC raised its position in Fresenius Medical Care by 8.4% in the 2nd quarter. Signaturefd LLC now owns 8,713 shares of the company’s stock worth $166,000 after purchasing an additional 672 shares during the period. Finally, Kimelman & Baird LLC purchased a new stake in Fresenius Medical Care in the 2nd quarter worth about $186,000. Hedge funds and other institutional investors own 8.25% of the company’s stock.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.